Your Science. Our Sequencers.

Our mission is to support scientists like you to accomplish your project, regardless of its scope. With rapid advancements in sequencing technology and capacity, we believe that genome sequencing as the gold standard for genetic analyses should be available to every scientist committed to the wide field of biology. We are your first choice genome sequencing provider, ready to meet your demands and to provide you with a genomic dataset – fast, affordable, and with outstanding service.

Genome sequencing for everyone – nothing can stop you now

To underscore our commitment to the scientific community, we have increased our sequencers fleet to five NovaSeq 6000s. This enables us to sequence additional 9000-14000 genomes per year. With the capacity gained, we can offer high-quality sequencing at competitive prices – also for smaller batches. We hence make genome sequencing accessible for all research groups, with sequencing demands in any quantity. 

Interpreting genomic data is vital – good thing that we have ten years of experience 

The sequencing of the whole genome provides a complete picture of an organism’s set of genetic information, which is especially important for rare disease and cancer research. Still, its interpretation is limited and remains challenging. As a pioneer in genetic diagnostics, we use our ten years of experience in solving cases to create and further develop new methods in genetics analyses. For more than one decade, we have successfully supported numerous projects from start to finish. We know what it takes to achieve the best results.

Tomorrow’s genetic research and diagnostics available today 

We are continuously growing and expanding to strengthen our position as your partner of choice for research projects – today and tomorrow. We are interested in developing solutions together with you, and we are your approachable partner with extensive, dedicated customer service. We use proven technology and adhere to the highest standards. All project steps are carried out in-house and under constant scientific supervision to maintain the best results. CeGaT is accredited according to CAP/CLIA and DIN EN ISO 15189, hence meeting high international laboratory standards. We are a privately held, independent company that only delivers fast, reliable, and trusted quality made in Germany.

Find more information about genome sequencing here.

Tumor Mutational Burden and Other Biomarkers Help to Assess the Efficacy of Immunotherapies

Immunotherapy has revolutionized the treatment of many types of cancer by taking advantage of the immune system’s ability to fight cancer cells. In the last few years, a growing number of immunotherapy-based clinical trials were launched to increase success rates further. Specific biomarkers help to stratify patients for the best treatment choice, and also to support the promising development of new immunotherapy combinations.

The center for Dermatooncology at the University hospital Tübingen conducted a prospective biomarker study (Forschner 2019) in cooperation with CeGaT GmbH. This study aimed to identify reliable biomarkers, which predict the patient’s response to anti-CTLA-4 and anti-PD-1 immunotherapy.

Tumor mutational burden (TMB) is a biomarker that has been described as particularly useful for immunotherapy and was thus assessed as part of this study. TMB refers to the number of mutations present in a cancer patients’ tumor and is quantified as mutations per million base pairs (mut/Mbp). Furthermore, repetitive liquid biopsies were collected to determine the concentration of circulating tumor DNA (ctDNA) during treatment. Several studies have shown that ctDNA levels are associated with treatment response and prognosis and could therefore serve as non-invasive predictive markers.

Within this study, we demonstrated that patients with a high TMB (>23.1) showed a significantly better response to therapy and, consequently, a better outcome compared to patients with TMB-low or TMB-intermediate tumors. Similarly, undetectable levels of ctDNA, or a >50% decrease of the cell-free DNA (cfDNA) concentration at the time of first follow-up (3w post treatment initiation) was significantly associated with therapy response and better overall survival.

The results of this study strengthen the increasing importance of the analysis of biomarkers such as TMB, ctDNA, or cfDNA in the prediction and early assessment of the effectiveness of immunotherapies.


CeGaT Research and Pharma Solution offers different methods of TMB analysis to meet the most diverse study requirements


At CeGaT, the TMB score can be evaluated based on different sequencing approaches. The best choice for a specific project depends on the underlaying scientific question and availability of patient material. Typically, the TMB score is assessed through whole-exome sequencing of the tumor tissue, as well as the corresponding normal tissue (e.g. blood sample). By comparing the variants detected in both samples, we can discriminate between tumor specific (somatic) mutations, and mutations present in every tissue of the patient.

However, recent studies have shown that the TMB score can also be effectively estimated if only a panel of genes gets sequenced, provided the sequencing panel covers a genomic region of at least 1,5 Mb (Buchhalter 2018). Thus, for many cases, it is not only sufficient but even more expedient to analyze a selected panel of genes. Therefore, we make use of our CeGaT somatic tumor panel which comprises more than 700 selected, cancer-related genes.

Clinical samples are very precious material and availability is often limited. A comparison of tumor and normal tissue might not always be possible. To meet this challenge, CeGaT uses the solution provided by Illumina, in which TMB score is evaluated based on tumor tissue analysis only: TruSight Oncology 500 (TSO500) comprises the next-generation sequencing based analysis of 523 cancer-relevant genes and their standardized bioinformatic assessment. No normal tissue is required.

For the most comprehensive results, CeGaT’s customers always receive information about the tumor’s microsatellite instability (MSI) in addition to TMB analysis – regardless of whether it is based on TSO500, whole-exome sequencing, or CeGaT somatic tumor panel sequencing. Besides TMB, MSI is another important biomarker for the patient’s response to immunotherapy.

Contact us in order to find out which TMB product is the best choice for your study.


Combine your TMB analysis with the following services offered by CeGaT Research and Pharma Solutions:

  • Detection and sequencing of certain immune subpopulations (e.g. CD4+, CD8+, PD-1+ T cells)
  • Detection of (neo)antigen-specific T cells
  • Microbiome analysis
  • T cell receptor (TCR) sequencing
  • Human leukocyte antigen (HLA) analysis
  • Transcriptome sequencing

Further information can be found here.


Forschner A, Battke F, Hadaschik D, Schulze M, Weißgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Döcker D, Biskup S. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study.
J Immunother Cancer. 2019 Jul 12;7(1):180. doi: 10.1186/s40425-019-0659-0.

Buchhalter I, Rempel E, Endris V, Allgäuer M, Neumann O, Volckmar AL, Kirchner M, Leichsenring J, Lier A, von Winterfeld M, Penzel R, Christopoulos P, Thomas M, Fröhling S, Schirmacher P, Budczies J, Stenzinger A. Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis. Int J Cancer. 2019. Feb 15; 144(4):848-858. doi: 10.1002/ijc.31878.

CeGaT Broadens Service Portfolio for Research and Pharmaceutical Industry

CeGaT GmbH expands its business division for sequencing services: Through “Research and Pharma Solutions”, the globally operating company offers individual approaches for projects from science and the pharmaceutical industry.

The Tübingen-based company, which was founded primarily as a genetic diagnostics provider, is constantly expanding its expertise and portfolio in the field of custom sequencing. It meanwhile offers services that go beyond sequencing services, such as immunomoritoring, liquid biopsy, and tumor mutation burden analyses. CeGaT is continuously investing in the newest technologies. With three company-owned NovaSeq 6000, large quantities of sample material can be analyzed within a very short time. By combining state-of-the-art equipment with human know-how, CeGaT supports numerous scientists in their work.

The repositioning is a response to the rising demand and addresses clients from the pharmaceutical industry. As a long-term partner, CeGaT provides support for the realization of their projects such as clinical studies.

Dr. Jiri Ködding, Director Operations, sees this transformation as an important step: “Our vision is to strengthen CeGaT’s position as the partner of choice for research institutions and pharmaceutical companies all over the world. Since long we have been offering more than just sequencing. The new name better describes what we stand for: Convincing individual solutions for scientific and pharmaceutical questions“.

You can find more information on the Research and Pharma Solutions portfolio here. CeGaT strives for the highest quality in the realization of research projects. For this reason, the company adopts the strict requirements of genetic diagnostics also for projects from science and the pharmaceutical sector. To guarantee high-quality standards and fast throughput times, all steps are carried out in-house. The entire process, from project design to the final report, is supervised by a dedicated project manager providing advice and support to the client. CeGaT is accredited according to CAP, CLIA, and DIN EN ISO 15189:2014.